View Sample PDF

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment.

1. 1. Overview 4
2. 1.1 Objectives of the Report 4
3. 1.2 Methodology 5
4. 1.3 Scope of the Report 6
5. 1.4 Executive Summary 7
7. 2. Technologies and Product Offering for High-Content Analysis 10
8. 2.1 Definition of High-Content Analysis and Why it is so Attractive a Discipline 11
9. 2.2 Classes of Measurements Possible with High-Content Analysis Approaches and Biologies Interrogated 14
10. 2.3 Instrumentation Platforms for High-Content Analysis 17
11. 2.3.1 High-Content Screening Technology 17
12. 2.4 Reagent and Assay Platforms for High-Content Analysis 24
13. 2.5 Cell-based Screening Technologies in Drug Development 28
14. 2.5.1 Applications of Cell-based Assays 28
15. 2.5.2 Pharma Drug Discovery Paradigm and Compound Screening 28
16. 2.5.3 High-Content Analysis in the Biopharmaceutical Industry 29
18. 3. Market Analysis of the High-Content Tools Space 31
19. 3.1 High-Content Analysis Market Size and Growth 31
20. 3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the High-Content Analysis Space 31
21. 3.3 Experimental and Research Trends in High-Content Analysis 33
22. 3.4 Challenges and Market Drivers in High-Content Analysis 38
23. 3.4.1 Barriers to High-Content Analysis 40
24. 3.4.2 Drivers of High-Content Analysis 41
25. 3.5 High-Content Analysis in Combination with RNAi 41
26. 3.6 Market Landscape of Instrumentation for High-Content Analysis 43
27. 3.7 Reagents and Assays Usage in High-Content Analysis 47
28. 3.8 Trends in High-Content Analysis Assays/Reagents Space-Major Product Vendors 50
29. 3.9 Emerging Market Trends in High-Content Analysis 52
30. 3.10 Market Forecasts for the High-Content Analysis Space 54
31. 3.11 Use of HCS in Pharmaceutical Companies 56
32. 3.12 Qualitative Opportunities and Challenges for Market Adoption 57
34. 4. Strategic Analysis of the High-Content Tools Space 58
35. 4.1 High-Content Analysis Market Structure 58
36. 4.2 Description of the Drug Discovery Marketplace and Definition of the Field 58
37. 4.3 Key Market Drivers and Challenges in the High-Content Analysis Space 59
38. 4.4 Consolidated Picture of the High-Content Analysis Marketplace 62
39. 4.5 High-Content Analysis Market Sectors and Growth Rate 64
40. 4.6 Vendors of High-Content Analysis Technology 64
42. 5. High-Content Analysis Technology Platforms 65
43. 5.1 Methods of Digital Imaging 65
44. 5.2 Fluorescence Microscopy 65
45. 5.3 Major High-Content Analysis Instrumentation 66
46. 5.3.1 High-Content Analysis Platforms to Support GPCR Screening 67
47. 5.4 High-Content Analysis Reagents 67
48. 5.5 Imaging Software 68
49. 5.6 Enterprise-Level IT Solution to Support High-Content Screening Experiments 68
50. 5.6.1 Image Analysis Algorithms 69
51. 5.7 Use of RNAi in High-Content Analysis 70
52. 5.8 Industry Alliance to Leverage RNAi and High-Content Analysis 70
53. 5.9 Emerging Trends in High-Content Analysis Technology Platforms 71
55. 6. High-Content Analysis in Drug Selection, Screening and Biomarker Discovery 72
56. 6.1 Stem Cells Used as a Drug Discovery Tool 73
57. 6.2 Cellular Systems Biology for Development of Toxicity Panels in Drug Safety Testing 73
58. 6.3 Drug Discovery Companies Marketing Cell-based Assays 74
59. 6.4 Companies Using Cell-based Assays in Drug Discovery Programs 77
60. 6.4.1 Phenotypic Drug Discovery (PDD) 77
61. 6.4.2 Application of Quantitative High-Throughput Screening to High-Content Analysis of Cell-based Assays 78
62. 6.4.3 Application of High-Content Fingerprinting to Oncology Drug Discovery: Focus on In vitro and In vivo Phenocopying and Cancer Stem Cell Analysis 78
63. 6.5 Target Discovery and Validation by RNAi Screening 78
64. 6.6 FLIM-FRET Methodology 78
65. 6.7 Multidimensional Fluorescence Imaging (MDFI) Technology 79
67. 7. Company Profiles and Glossary of Terms in High-Content Analysis 80
68. 7.1 Acumen Pharmaceuticals, Inc. 80
69. 7.2 Applied Biosystems 80
70. 7.3 Becton, Dickinson and Company 84
71. 7.4 Beckman Coulter, Inc. 86
72. 7.5 Blueshift Biotechnologies, Inc. 91
73. 7.6 Caden Biosciences, Inc. 91
74. 7.7 Cellomics, Inc. 91
75. 7.8 Cellumen, Inc. 92
76. 7.9 Cenix BioScience 92
77. 7.10 Cyntellect 93
78. 7.11 Definiens 93
79. 7.12 DiscoveRx 93
80. 7.13 Euroscreen 94
81. 7.14 Evotec Technologies 94
82. 7.15 Fisher BioImage 94
83. 7.16 General Electric, GE Healthcare Advanced Systems 95
84. 7.17 Guava Technologies, Inc. 96
85. 7.18 Millipore 96
86. 7.19 Molecular Devices Corporation 97
87. 7.20 NIH Chemical Genomics Center 100
88. 7.21 PerkinElmer 100
89. 7.22 Spotfire 104
90. 7.23 Translational Genomics Research Institute 104
91. 7.24 Vala Sciences, Inc. 105
93. 8. Glossary of Terms in the High-Content Analysis Space 106
96. LIST OF FIGURES
98. Figure 2.1: Scope of Biological Parameters Addressed via a Typical High-Content Analysis Experiment 13
99. Figure 2.2: Classes of Assays in Life Science Research and Drug Discovery Illustrating the Relationship between Cell-based Assays and High-Content Analysis 14
100. Figure 2.3: New Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Screening 16
101. Figure 2.4: Cumulative and New Drug Targets 30
102. Figure 3.1: Breakout of Market Survey Respondents by Geographical Location 31
103. Figure 3.2: Breakout of Market Survey Respondents by Affiliation-Academic, Commercial, Vendor 31
104. Figure 3.3: Segmentation of Respondent Pool Based upon Usage of High-Content Analysis in its Research Activities 32
105. Figure 3.4: Segmentation of the Survey Respondent Pool Based upon the Length of Time they have been Using High-Content Analysis in their Research Activities 32
106. Figure 3.5: Number of Parameters Studied Simultaneously in High-Content Analysis Assays-Multivariate (Multi-Parameter) Analyses 34
107. Figure 3.6: Key Biological Processes Studied Utilizing High-Content Analysis Tools 35
108. Figure 3.7: Breakout of High-Content Analysis Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target) 36
109. Figure 3.8: Breakout of High-Content Analysis Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets) 36
110. Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using High-Content Analysis-based Approaches are Growing in Importance or Declining? 37
111. Figure 3.10: In Which Environment are High-Content Analysis Assays Performed-Primary Screen, Secondary Screen, ADME/Tox Screen? 38
112. Figure 3.11: Key Challenges Faced by the Research Community in their Practice of High-Content Analysis 39
113. Figure 3.12: Various Drivers that are Leading the Research Community to Perform High-Content Analysis 40
114. Figure 3.13: High-Content Analysis Together with RNAi-Current and Future Experimental Formats 42
115. Figure 3.14: High-Content Analysis Together with RNAi-Number of Experiments Performed Per Month by the Survey Respondent Pool 42
116. Figure 3.15: Growing and Steady Usage of the Various Formats where RNAi is coupled with High-Content Analysis 43
117. Figure 3.16: Penetration of the Different High-Content Analysis Instrumentation Platforms into the Marketplace 44
118. Figure 3.17: Instrumentation Platforms for High-Content Analysis Ranked by Top Choice and Second Tier 45
119. Figure 3.18: High-Content Analysis Instrumentation and where they Lie on the Throughput Curve 46
120. Figure 3.19: Top Instrumentation Value Drivers in the High-Content Analysis Space 46
121. Figure 3.20: Important Sub-Cellular Features Studied via High-Content Analysis Approaches 47
122. Figure 3.21: Breakout of End-Point Versus Kinetic Assays in the High-Content Analysis Space 48
123. Figure 3.22: Types of Cellular Targets Studied Using High-Content Analysis Approaches 48
124. Figure 3.23: Top-most Target Class Being Studied Utilizing High-Content Analysis Approaches 49
125. Figure 3.24: Distribution of High-Content Analysis Experiments across the Respondent Pool-Number of Experiments Performed Per Week 49
126. Figure 3.25: Average Reagent/Assay Costs Per High-Content Analysis Experiment 50
127. Figure 3.26: Stratification of Reagent/Assay Suppliers into the High-Content Analysis Space 51
128. Figure 3.27: Monthly Reagent/Assay Purchases for High-Content Analysis by the End-user Community from the Various Vendors Offering Products into the Space 51
129. Figure 3.28: Growth or Decline in Importance of the Various High-Content Analysis Vendors to the End-user Community 52
130. Figure 3.29: Percentage of High-Content Analysis Experiments that Involve GFP across the Market Landscape 53
131. Figure 3.30: Breakout of High-Content Analysis Reagents Marketplace: Home-Brew Versus Off-the-Shelf 53
132. Figure 3.31: Breakout of Spending into the Various Components of the High-Content Analysis Discipline 54
133. Figure 3.32: Forecast Growth of the Total Screening Space-Broken-out by Primary Screening, Secondary Screening (includes High-Content Analysis as a Subset) and ADME/Tox, 2004-2010 55
134. Figure 3.33: Forecast Growth of the Screening Space-Broken-out by Cell-based Assays and Biochemical Assays, 2004-2010 56
135. Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of High-Content Analysis in the Space 61
136. Figure 4.2: Relative Size and Position of the High-Content Analysis Space in the Overall Scheme of the Life Science Tools Marketplace 63
137. Figure 5.1: High-Content Analysis-Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus 69
138. Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes 72
139. Figure 6.2: GPCR Assay Technologies 73
142. LIST OF TABLES
144. Table 2.1: Comparison of the Key Features of High-Content Analysis and High-Content Screening 12
145. Table 2.2: Impact of High-Content Analysis on Drug Discovery-Several Drivers are Addressed 12
146. Table 2.3: Biological Application Areas Associated with High-Content Analysis 13
147. Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (High-Content Analysis) 14
148. Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors 15
149. Table 2.6: Multi-Parameter High-Content Analysis Assays to Study Biological Systems in Life Science Research and Drug Discovery-Demonstrates the Breadth and Scalability of the High-Content Analysis Approach 17
150. Table 2.7: Companies Offering Systems for High-Throughput Imaging 19
151. Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for High-Content Analysis-I 20
152. Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for High-Content Analysis-II 20
153. Table 2.10: Price Points and Target Markets of the Various High-Content Analysis Instrument Platforms 21
154. Table 2.11: Companies Offering Flow Cytometry Products and Services 21
155. Table 2.12: Integrated Product Platforms Offered by the Different High-Content Analysis Vendors 23
156. Table 2.13: Biologies interrogated by Cellomics High-Content Analysis Assays 24
157. Table 2.14: Cellomics HitKit® High-Content Analysis Assay/Reagent Kits and the Therapeutic Areas where they Find Application 25
158. Table 2.15: Assay/Reagent Portfolio of Millipore Addressing High-Content Analysis Applications 26
159. Table 2.16: Cell Lines for GPCR High-Content Analysis that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform 26
160. Table 2.17: Examples of High-Content Screens 29
161. Table 3.1: What Fraction of High-Content Analysis Assays are Cell-based Versus Biochemical-based 33
162. Table 4.1: Comparison of the Key Features of High-Content Analysis and High-Content Screening 59
163. Table 4.2: Snapshot of the Various High-Content Analysis Assays Demonstrating the Scalability of this Discipline 61
164. Table 5.1: Modes of Digital Imaging 65
165. Table 5.2: Modes of Fluorescence 65
166. Table 5.3: Major High-Content Analysis Instrumentation 66
167. Table 5.4: Image Analysis Algorithms 69